Clinical Trial Update: Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study [NA]

View source ↗

Summary

The SIMPLIFY sub-study reports results on discontinuing Dornase alfa in people with cystic fibrosis who are on highly effective CFTR modulator therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Pulmozyme (dornase alfa)

Snippet

Sponsor: Nicole Hamblett | Conditions: Cystic Fibrosis | NA | Status: COMPLETED | Results posted: 2024-11-26